Back to search
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype trials you may qualify forGlioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization plat…
Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the B…
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblast…
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is:…
The goal of this clinical trial is to validate ONCOhabitats, an advanced imaging software, as a medical device for the clinical management of IDH-wildtype gliob…
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatmen…
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.